Omada Health (NASDAQ:OMDA) Sees Unusually-High Trading Volume After Earnings Beat

Shares of Omada Health, Inc. (NASDAQ:OMDA) saw strong trading volume on Friday following a better than expected earnings announcement. 1,345,380 shares traded hands during mid-day trading, an increase of 12% from the previous session’s volume of 1,204,712 shares.The stock last traded at $13.67 and had previously closed at $13.60.

The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.12. The business had revenue of $75.85 million during the quarter.

Key Stories Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

Analysts Set New Price Targets

Several brokerages recently commented on OMDA. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of Omada Health in a research report on Thursday, January 22nd. Morgan Stanley cut their price objective on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Omada Health in a report on Thursday, January 22nd. The Goldman Sachs Group restated a “buy” rating and set a $26.00 target price on shares of Omada Health in a research note on Friday, January 16th. Finally, BMO Capital Markets decreased their price target on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.90.

Insider Transactions at Omada Health

In related news, President Wei-Li Shao sold 5,618 shares of Omada Health stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the transaction, the president directly owned 69,079 shares of the company’s stock, valued at $1,114,244.27. This trade represents a 7.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Sean P. Duffy sold 40,796 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $15.95, for a total transaction of $650,696.20. Following the sale, the chief executive officer directly owned 126,644 shares in the company, valued at $2,019,971.80. This trade represents a 24.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 276,893 shares of company stock valued at $4,336,787 in the last quarter.

Institutional Trading of Omada Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Omada Health during the 3rd quarter valued at about $38,000. Raymond James Financial Inc. bought a new position in shares of Omada Health in the second quarter valued at $32,000. Quarry LP acquired a new position in Omada Health in the 4th quarter valued at about $29,000. TD Waterhouse Canada Inc. acquired a new position in Omada Health in the 4th quarter valued at about $32,000. Finally, Rakuten Investment Management Inc. bought a new position in Omada Health in the 3rd quarter valued at about $49,000.

Omada Health Price Performance

The stock has a market capitalization of $813.64 million and a price-to-earnings ratio of -56.20. The company’s 50-day simple moving average is $14.03 and its 200-day simple moving average is $18.68.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.